<DOC>
	<DOC>NCT01944982</DOC>
	<brief_summary>To determine safety profile of immunotherapy with natural killer cells and activated expanded (NKAEs) after salvage chemotherapy in relapsed/refractory paediatric T cell lymphoblastic leukaemia and lymphoma.</brief_summary>
	<brief_title>Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<criteria>Patients aged between 0 and 21 years with relapsed or refractary acute lymphoblastic leukemia or Tcell lymphoblastic lymphoma. Lansky Index &gt; 60%. Left ventricular ejection fraction &gt; 39%. Negative HIV serology. Provide informed consent in accordance with current legislation. Patients with a history of poor compliance. Patients not valid after psychosocial evaluation Severe (4) functional organ disorders (hepatic, renal, respiratory) according to NCI CTCAE v3 criteria</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>NKAEs</keyword>
	<keyword>Expanded haploidentical natural killer cells</keyword>
	<keyword>Activated natural killer cells</keyword>
</DOC>